Nongma Sawadogo leads work on women’s and children’s health for the FCI Program of Management Sciences for Health (MSH) in Burkina Faso, and Alanna Savage is senior communications specialist for the FCI Program of MSH.
Burkina Faso has unacceptably high national rates of maternal and newborn mortality, but health indicators are the poorest in the Sahel, North and East where many more women and children are dying from preventable causes due to poor quality of care.
With support from Johnson & Johnson and working closely with the Division of Family Health, the Ministry of Health, UNFPA, the School of Public Health and national midwifery associations, the FCI Program of MSH is leading an intensive training, supervision and mentorship program to improve midwives’ mastery of life-saving clinical skills. The training program covers three modules: (1) compassionate care for mothers and newborns, (2) Helping Mothers Survive, and (3) Helping Babies Breathe.
This month, the FCI Program of MSH is featuring stories about fearless champions, powerful evidence, and advocacy wins from the Rights & Realities archive. Here is a recap of the fearless stories we shared on Twitter and Facebook February 1 -10.
On December 15, MSH, Gynuity Health Projects and Jhpiego hosted a one-hour webinar to share innovations – interventions, technologies, and distribution approaches – that have the potential to increase access to and use of misoprostol for postpartum hemorrhage (PPH), the leading cause of maternal death. This webinar:
Highlighted innovative ways that countries are expanding access to and use of misoprostol for PPH
Showed how successful innovations can be scaled up for national impact
Knowledge Management Specialist & Associate Program Manager, One Million Community Health Workers Campaign-Millennium Promise, Ghana
Program Associate, Gynuity Health Projects, USA
Saving Mothers Project, Mara Region, Tanzania and University of Ottawa, Canada
Monitoring, Evaluation and Research Director, Jhpiego, Afghanistan
Senior Technical Advisor, FCI Program of Management Sciences for Health (MSH)
Listen to the webinar and download the presentation slides here.
Shafia Rashid is a Senior Technical Advisor for the FCI Program of Management Sciences for Health.
In Senegal, approximately 1,800 women lose their lives every year while giving birth. The major cause of these deaths is uncontrolled bleeding after childbirth, or postpartum hemorrhage (PPH). More than half of Senegalese women live in rural areas and have limited access to well-equipped health facilities that can prevent or treat many of these deaths. Many women give birth, attended by matrones or volunteer birth attendants, in maternity huts. Recognized as essential health care providers by their communities, matrones have some formal training and are now registered with the Ministry of Health (MoH).
To effectively prevent or treat PPH, women need access to uterus-contracting drugs, or uterotonics, such as oxytocin or misoprostol. The recommended uterotonic, injectable oxytocin, requires cold storage and technical skill to administer. Misoprostol is a safe and effective alternative where oxytocin isn’t available or feasible; it doesn’t need refrigeration and is easy to use—particularly important features for use in remote, rural areas.
From 2013 to 2014, the Government of Senegal’s Direction of Reproductive Health and Child Survival, in partnership with USAID and Gynuity Health Projects, examined the use of misoprostol (600 mcg oral) or oxytocin (10 UI) via Uniject® for prevention of PPH at the community level. Matrones were trained to assist with deliveries and administer the designated intervention. According to the study, both misoprostol and oxytocin in Uniject® were equally effective and safe in preventing PPH, and matrones posted at the health huts were capable of administering the medicine they were assigned. Continue reading “Misoprostol for postpartum hemorrhage: Empowering health workers to save lives”
Melissa Wanda Kirowo is advocacy project officer for FCI Program of Management Sciences for Health in Kenya.
This blog post provides an update to an earlier post.
The Kenya Constitution states that every person has the right to the highest attainable standard of health, including reproductive health. To realize this right, every person must have access to high-quality, life-saving medicines.
Recently, the government achieved great strides toward making this right to health a reality for its citizens. For the first time, the Kenya Essential Medicines List 2016 (KEML) included misoprostol in the oxytocics section, indicating its use for the prevention and treatment of postpartum hemorrhage (PPH), excessive bleeding after childbirth and a leading cause of maternal death. Misoprostol is stable at room temperature, available in pill form, and inexpensive. Because of these advantages and the drug’s wide availability, misoprostol may be a woman’s only chance for surviving PPH in settings with limited infrastructure and a shortage of skilled birth attendants–like many parts of Kenya. Continue reading “Advocacy success story: Kenya approves misoprostol for PPH”
SMNLW participant Maria Fernandez Elorriaga is the principal investigator and technical coordinator of a study investigating the use of the World Health Organization (WHO) Safe Childbirth Checklist to improve the quality of institutional delivery in Mexico. Maria is also co-investigator on two more studies of implementation science in maternal and perinatal care. In addition, Maria has worked as a primary and community care nurse in Spain, as a regional nutrition coordinator in Malawi and as child health and nutrition coordinator in the Sahrawi refugee camps in Tindouf, Algeria. Continue reading “Global Leaders in Maternal Newborn Health: Maria Fernandez Elorriaga (Mexico)”
The FCI Program of MSH will be at the 17th General Membership Meeting of the Reproductive Health Supplies Coalition in Seattle. Please join us for a breakfast and panel discussion on strategies for increasing access to misoprostol and oxytocin to prevent and treat postpartum hemorrhage and magnesium sulfate to treat pre-eclampsia/eclampsia.
Shafia Rashid is Senior Technical Advisor at the FCI Program of Management Sciences for Health.
In June 2013, Imtiaz Kamal–a crusader for midwifery and women’s health–celebrated Pakistan’s official recognition of the essential maternal health medicine, misoprostol, which has proven easy to administer, safe and effective for preventing and treating excessive postpartum bleeding. “Given the high prevalence of home births,” Imtiaz explained, “we need to invest in solutions, such as misoprostol, that save lives now, until we can achieve the long-term goals of strengthening health systems and increasing rates of facility births.” Continue reading “EML Search: New resource for reproductive and maternal health advocates”
Misoprostol is a safe and effective medicine that can prevent and treat postpartum hemorrage, a leading cause of maternal death worldwide. Join our advocacy workshop at Women Deliver on May 16 to develop strategies to influence supportive misoprostol policies!
Read more posts on misoprostol for postpartum hemorrhage here.